BioMatrix Partners with Genentech

BioMatrix SpRx has selected as an authorized specialty pharmacy provider of Genentech's new drug, Hemlibra(emicizumab-kxwh). The product is indicated for pediatric and adult patients who have hemophilia A with inhibitors.

Receiving Breakthrough Therapy Designation by the FDA in 2015, Hemlibra is the first self-administered, subcutaneous therapy for hemophilia. Data from ongoing clinical studies indicates once weekly injections substantially reduce bleed rates.

Chief clinical officer David McCormick shares, "We are thrilled to partner with Genentech to offer Hemlibra. We have a long history of supporting patients with inhibitors and understand the unique challenges this community faces. We have witnessed the quality of life improvements this drug can provide, and are so proud to play our role in helping patients experience better health."

BioMatrix SpRx, a portfolio company of Acon Investments and Triton Pacific Capital Partners, LLC., offers comprehensive nationwide specialty pharmacy services and digital health technology solutions for a range of chronic health conditions.